AdvaMedDx Announces Newly Elected Members of the Board of Directors

You are here

AdvaMedDx Announces Newly Elected Members of the Board of Directors

January 28, 2013

WASHINGTON, D.C. – AdvaMedDx, a division of the Advanced Medical Technology Association (AdvaMed) that is focused solely on opportunities and challenges facing companies that develop and manufacture medical diagnostic technologies, has elected several new members to its board of directors.

“AdvaMedDx works with policy makers, patients and health care professionals to improve patient care and reduce overall health care costs. We welcome the broad global experience that the new board members will bring to these efforts,” said Vincent A. Forlenza, BD Chairman, CEO and president and AdvaMedDx board chair. “We look forward to working with the Administration and the new Congress on payment system reforms that provide incentives for the development of new diagnostics for early detection and disease prevention. Together, we also will continue to advocate for the implementation of a risk-based approach to the regulation of diagnostics to ensure the safety of all tests and to advance faster patient access.”

“There is significant work to be done in 2013, and we are pleased to have this group of veteran industry leaders join our board,” said Andrew Fish, AdvaMedDx executive director. “The collective experience and insight of our board members is of the utmost importance as we work with Congress on payment reform, including seeking the reintroduction of House bill H.R. 6446 and the MODDERN Cures Act, and other key initiatives.”

The new members of the board are:

  • Brian Blaser, executive vice president, diagnostic products, Abbott Diagnostics
  • Brian Armstrong, chief financial officer, bioMerieux
  • William “Bill” Hawkins III, president and chief executive officer, Immucor
  • Eric Compton, worldwide president, Ortho Clinical Diagnostics
  • Roland Diggelmann, chief operating officer, Roche Diagnostics

###

AdvaMedDx member companies produce innovative, safe and effective in vitro diagnostic tests that facilitate evidence-based medicine, improve quality of patient care, promote wellness, enable early detection of disease and reduce overall health care costs. Functioning as an association within AdvaMed, AdvaMedDx is dedicated to the issues facing in vitro diagnostic companies both in the United States and abroad.

For more information, please contact: Ashley McMaster @ (202) 434-7245